- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 213/50 - Ketonic radicals
Patent holdings for IPC class C07D 213/50
Total number of patents in this class: 243
10-year publication summary
|
23
|
29
|
11
|
14
|
16
|
12
|
7
|
5
|
8
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Biosplice Therapeutics, Inc. | 170 |
9 |
| Syngenta Limited | 454 |
7 |
| PTC Therapeutics, Inc. | 487 |
6 |
| Mycovia Pharmaceuticals, Inc. | 41 |
6 |
| Chem-Master International, Inc. | 11 |
5 |
| Givaudan SA | 1893 |
5 |
| Johnson Matthey Public Limited Company | 1866 |
5 |
| Centre National de La Recherche Scientifique | 10498 |
4 |
| The Board of Trustees of the University of Illinois | 2711 |
4 |
| Purdue Pharma L.P. | 500 |
4 |
| Lighthouse Pharmaceuticals, Inc. | 11 |
4 |
| The Regents of the University of California | 20035 |
3 |
| Syngenta Crop Protection AG | 6100 |
3 |
| Epizyme, Inc. | 374 |
3 |
| Karyopharm Therapeutics Inc. | 141 |
3 |
| Novaled GmbH | 446 |
3 |
| The Research Foundation for The State University of New York | 1631 |
3 |
| The Research Foundation of State University of New York | 442 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2866 |
3 |
| Xenthera, Inc. | 4 |
3 |
| Other owners | 157 |